HUMANIGEN, INC.


Associated tags: Health, Biotechnology, COVID-19, Pharmaceutical, Clinical Trials, Pharmaceutical industry, Research, Patient

Lenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings Journal

Retrieved on: 
Tuesday, September 1, 2020

The manuscript , titled GM-CSF neutralization with lenzilumab in severe COVID-19 patients: A case-control study was published in Mayo Clinic Proceedings, a premier peer-reviewed journal.

Key Points: 
  • The manuscript , titled GM-CSF neutralization with lenzilumab in severe COVID-19 patients: A case-control study was published in Mayo Clinic Proceedings, a premier peer-reviewed journal.
  • The study involved a total of 39 patients, including 12 treated with lenzilumab, and 27 contemporaneous matched control patients who received standard of care treatment.
  • Lenzilumab treatment was associated with a reduction in risk of progression to IMV and/or death compared to matched controls (8% vs. 41%, p=0.07).
  • Patients treated with lenzilumab were discharged in a median of five days versus 11 days in the control arm (p=0.008).

Humanigen Appoints Edward P. Jordan as Chief Commercial Officer

Retrieved on: 
Monday, August 24, 2020

Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, today announced the appointment of Edward P. Jordan, MBA, to Chief Commercial Officer, a new role that will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, effective immediately.

Key Points: 
  • Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, today announced the appointment of Edward P. Jordan, MBA, to Chief Commercial Officer, a new role that will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, effective immediately.
  • Prior to DBV Technologies, Mr. Jordan held senior executive roles at AMAG Pharmaceuticals and Teva Pharmaceuticals.
  • Mr. Jordan began his career at Schering-Plough, prior to the acquisition by Merck, and spent 18 years in sales and marketing leadership positions.
  • Mr. Jordan received dual undergraduate degrees from The University of Rhode Island and an MBA from Southern New Hampshire University.

Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil

Retrieved on: 
Monday, August 10, 2020

Humanigen is working with Clinical Trial & Consulting (CTI), recently named the top global contract research organization, to conduct this trial in Brazil.

Key Points: 
  • Humanigen is working with Clinical Trial & Consulting (CTI), recently named the top global contract research organization, to conduct this trial in Brazil.
  • We hope that expanding the study of lenzilumab to research centers in Brazil, a country with surging rates of COVID-19, will offer patients much needed access to a leading COVID-19 therapeutic candidate.
  • Currently, Brazil has the second highest reported rates of COVID-19 infection in the world, second only to the US.
  • We are proud to collaborate with our colleagues at Humanigen to extend the reach of the Phase III study of lenzilumab and bring a potential treatment option to those in need.

REMINDER: Humanigen to Present at the BTIG Virtual Biotechnology Conference 2020

Retrieved on: 
Monday, August 10, 2020

Humanigen, Inc. , (HGEN) (Humanigen), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and business update at the BTIG Virtual Biotechnology Conference 2020 today, August 10, 2020 at 2:00 pm Eastern Time.

Key Points: 
  • Humanigen, Inc. , (HGEN) (Humanigen), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and business update at the BTIG Virtual Biotechnology Conference 2020 today, August 10, 2020 at 2:00 pm Eastern Time.
  • The conference is being held in a virtual format.
  • An archived replay of the event will be available on the Company website for 30 days following the event.
  • We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.

Humanigen Appoints Bob Atwill as Head of Asia-Pacific Region

Retrieved on: 
Thursday, August 6, 2020

Mr. Atwill will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, and will initially serve on a consultancy basis.

Key Points: 
  • Mr. Atwill will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, and will initially serve on a consultancy basis.
  • Mr. Atwill has more than 30 years of experience in the global healthcare industry across the pharmaceutical, biotechnology and cellular therapy sectors.
  • Mr. Atwill received his MBA from Ashridge Management College in the UK and has participated in Executive/President programs at Yale University and UCLA.
  • I am honoured to assist in progressing lenzilumab and the Humanigen pipeline in Australia and more broadly across the Asia-Pacific Region.

Humanigen to Present at the BTIG Virtual Biotechnology Conference 2020

Retrieved on: 
Wednesday, August 5, 2020

Humanigen, Inc. , (HGEN) (Humanigen), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and business update at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11th, 2020 at 2:00 pm Eastern Time.

Key Points: 
  • Humanigen, Inc. , (HGEN) (Humanigen), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and business update at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11th, 2020 at 2:00 pm Eastern Time.
  • The conference is being held in a virtual format.
  • An archived replay of the event will be available on the Company website for 30 days following the event.
  • Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.

Humanigen to Host Investor Conference Call to Discuss NIH’s Selection of Lenzilumab for Big Effect Trial

Retrieved on: 
Monday, August 3, 2020

Humanigen will host the conference call and webcast today at 4:30 p.m. EDT.

Key Points: 
  • Humanigen will host the conference call and webcast today at 4:30 p.m. EDT.
  • To participate on the conference call, please dial toll free (833) 714-0938 or toll number +1 (778) 560-2680.
  • A simultaneous webcast of the call and presentation can be accessed by visiting: https://event.on24.com/wcc/r/2551709/C2EEA514D519C23B4A3E9E777BF19147 .
  • In addition, a replay of the webcast will be available on the company website for 30 days following the event.

Timothy Morris Joins Humanigen as Chief Operating Officer and Chief Financial Officer

Retrieved on: 
Monday, August 3, 2020

Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced the appointment of Timothy E. Morris to the newly created role of Chief Operating Officer and Chief Financial Officer, effective immediately, reporting to Dr. Cameron Durrant, Chief Executive Officer.

Key Points: 
  • Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced the appointment of Timothy E. Morris to the newly created role of Chief Operating Officer and Chief Financial Officer, effective immediately, reporting to Dr. Cameron Durrant, Chief Executive Officer.
  • Mr. Morris has more than two decades of experience serving in executive roles at public biotechnology companies.
  • He most recently served as Chief Financial Officer of Iovance, leading the companys raise of over $1 billion in equity, including a recent $600 million secondary offering.
  • Mr. Morris has been a member of the Humanigen Board of Directors since 2016.

National Institutes of Health Selects Humanigen’s Lenzilumab for its COVID-19 Big Effect Trial

Retrieved on: 
Monday, July 27, 2020

This trial builds on initial data from NIAIDs Adaptive COVID-19 Treatment Trial (ACTT) that demonstrated Gileads investigational antiviral, remdesivir, may improve time to recovery in hospitalized patients with COVID-19.

Key Points: 
  • This trial builds on initial data from NIAIDs Adaptive COVID-19 Treatment Trial (ACTT) that demonstrated Gileads investigational antiviral, remdesivir, may improve time to recovery in hospitalized patients with COVID-19.
  • BET will evaluate the combination of lenzilumab and remdesivir on treatment outcomes versus placebo and remdesivir in hospitalized COVID-19 patients.
  • We have been encouraged by the lenzilumab efficacy and safety data demonstrated in the compassionate use series in COVID-19 patients and are thrilled that NIH selected lenzilumab to be part of its Big Effect Trial, said Cameron Durrant, MD, MBA, chief executive officer of Humanigen.
  • With data from the BET and our ongoing Phase III study, we will have data from approximately 500 hospitalized COVID-19 patients.

Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab

Retrieved on: 
Thursday, July 16, 2020

Humanigen is a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys lead therapeutic candidate.

Key Points: 
  • Humanigen is a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys lead therapeutic candidate.
  • Based on lenzilumabs promising clinical data, we are pleased to expand our relationship with Catalent to solidify our ability to manufacture and supply lenzilumab, commented Cameron Durrant, MD, MBA, Chief Executive Officer of Humanigen.
  • Catalent has partnered closely with Humanigen to develop and supply lenzilumab for clinical trials, commented Karen Flynn, President of Catalent Biologics and Chief Commercial Officer.
  • Lenzilumab was originally manufactured in Catalents Madison facility using Catalent Biologics proprietary GPEx cell line development technology.